Jafron Biomedical Co.,Ltd. (SHE:300529)

Market Cap	15.32B -33.3%
Revenue (ttm)	2.04B -22.6%
Net Income	481.79M -40.1%
EPS	0.63 -37.8%
Shares Out	774.36M
PE Ratio	31.44
Forward PE	27.97
Dividend	0.80 (4.04%)
Ex-Dividend Date	May 26, 2025

Volume	4,603,501
Average Volume	5,427,153
Open	20.05
Previous Close	20.04
Day's Range	19.77 - 20.15
52-Week Range	19.19 - 27.30
Beta	0.43
RSI	39.34
Earnings Date	Apr 28, 2026

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/buc...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1989
• Employees: 2,500
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300529

Financial Performance

In 2024, Jafron Biomedical's revenue was 2.68 billion, an increase of 39.27% compared to the previous year's 1.92 billion. Earnings were 820.20 million, an increase of 87.91%.